We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects.
- Authors
Witte, Robert S.; Pruitt, Brian; Tormey, Douglass C.; Moss, Scot; Rose, David P.; Carbone, Paul P.; Ramirez, Guillermo; Falkson, Geoffrey; Falkson, Hendre; Pretorius, Florence J.; Witte, R S; Pruitt, B; Tormey, D C; Moss, S; Rose, D P; Falkson, G; Carbone, P P; Ramirez, G; Falkson, H; Pretorius, F J
- Abstract
Tamoxifen and trioxifene are antiestrogens that appear to have different endocrine effects when tested in rats. Whereas tamoxifen has considerable clinical activity, trioxifene is a new antiestrogen with undefined clinical activity. Thirty-six patients were treated with graded doses of trioxifene. The low-dose group (0.5 to 12 mg/m2 twice daily) had a 21% response rate in 24 subjects, and the high-dose group (40 to 100 mg/m2 twice daily) had a 33% response rate in 12 patients (P = 0.13). The time to treatment failure was 67 days and 178 days for the low- and high-dose groups, respectively. Toxicities were non-dose dependent; those of moderate frequency included leukopenia (41%) and nausea (31%). Tamoxifen reduced both prolactin and inducible growth hormone (GH). Trioxifene, although reducing prolactin, differed from tamoxifen in that an increase in inducible GH occurred. Furthermore, a striking dose-dependent decrease in luteinizing hormone and lesser decrease in follicle-stimulating hormone occurred only in the trioxifene-treated patients. This implies an intrinsic estrogenic action of trioxifene in man. Trioxifene is no more efficacious than tamoxifen and has more toxicity.
- Publication
Cancer (0008543X), 1986, Vol 57, Issue 1, p34
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19860101)57:1<34::AID-CNCR2820570109>3.0.CO;2-W